Fulgent Genetics, Inc. Common Stock (FLGT)
Fulgent Genetics, Inc. (FLGT) is a healthcare technology company specializing in genetic testing and related services. It provides comprehensive genetic testing solutions for healthcare providers, commercial partners, and consumers, leveraging advanced genomic analysis to assist in disease diagnosis, personalized medicine, and research. Founded in 2011, the company has evolved to become a significant player in the genetic testing industry, offering a wide array of tests in areas such as oncology, reproductive health, and rare diseases.
Company News
Fulgent Genetics reported Q2 earnings that exceeded analyst expectations, with revenue of $82 million, representing a 15% year-over-year increase, despite a 56% decrease in adjusted net income.
Law firm Bragar Eagel & Squire is investigating potential securities law violations by GoHealth, Semler Scientific, ADTRAN, and Fulgent Genetics, following DOJ investigations and financial reporting issues.
The Schall Law Firm is investigating potential securities law violations by Fulgent Genetics, Inc. related to the company's disclosure of a civil investigative demand from the DOJ regarding potentially false claims filed under the Uninsured Program.
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007 in treating various types of cancer. See why FLGT stock is a Hold.